Shares rallied about 300% in December after the company announced a US HIV licensing deal with Vyera Pharmaceuticals.
The company plans to submit Part 2 and 3 of their BLA for leronlimab for HIV combo in January. Once accepted, the BLA should be approved in Q2 2020.
CytoDyn is making good progress with its cancer trials; a replication of the stunning results seen in the first two patients in a higher number of patients would be ground-breaking.
2020 is likely to be a transformational year for the company with many catalysts ahead.
If its potential in non-HIV indications like cancer, NASH, GvHD and MS (and other diseases where CCR5 is involved) is validated, leronlimab might turn out to be a mega-blockbuster.
Editor's note: Seeking Alpha is proud to welcome Jannik Reiners as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free